Hoping to repeat its phase II success, Aldeyra Therapeutics Inc. enrolled the first patient in its pivotal phase III trial testing a topical version of its aldehyde trap, reproxalap, in ichthyosis associated with Sjögren-Larsson syndrome (SLS), a rare disease for which there are no approved therapies.